Chua K, Laurent F, Coombs G, Grayson ML, Howden BP

Antimicrobial resistance: Not community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician’s guide to community MRSA - its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis 2011; 52(1): 99-114.

32. Köck R, Becker K, Cookson B et al. Methicillin resistant Staphylococcus aureus (MRSA): burden of disease and control challenges in Europe. Euro Surveill 2010; 15(41): 19688.

33. Li S, Skov RL, Han X, et al. Novel types of staphylococcal cassette chromosome mec elements identified in clonal complex 398 methicillin resistant Staphylococcus aureus strains, Antimicrob Agents Chemother 2011; 55(6): 3046-50.

34. Otter JA, French GL. Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Europe.

Lancet Infect Dis 2010; 10(4): 227-39.

35. Stefani S, Chung DR, Lindsay JA et al. Meticillin resistant Staphylococcus aureus (MRSA): global epidemiology and harmonisation of typing methods. Int J Antimicrob Agents 2012; 39(4):

273-82.

36. Desen A, Di Guilmi AM, Vernet T, Dideberg O. Molecular mechanisms of antibiotic resistance in gram positive pathogens. Current Drug Targets-Infectious Disord 2001; 1: 63-77.

37. Woodford N. Biological counterstrike: antibiotic resistance mechanisms of gram positive cocci. Clin Microbiol Infct 2005; 11: 2-21.

38. Walsh C. Molecular mechanisms that conferantibacterial drug resistance. Nature 2000; 406: 775-81.

39. Bisognano C, Vaudaux P, Rohner P, Lew DP, Hooper DC. Induction of fibronectin binding proteins and increased adhesion of quinolone resistant Staphylococcus aureus by subinhibitory leveles of ciprofloxacin. Antimicrob Agents Chemother 2000; 44: 1428-37.

40. Sürücüoğlu S. Gram pozitif bakterilerde direncin moleküler temelleri.

In: Yüce A, Çakır N (eds). Hastane İnfeksiyonları. 2.baskı. İzmir:

Güven Kitabevi; 2009. 117-25.

41. Jones RN, Kohno S, Ono Y, Ross JE, Yanagihara K. ZAAPS International Surveillance Program (2007) for linezolid resistance:

results from 5591 Gram positive clinical isolates in 23 countries. Diagn Microbiol Infect Dis 2009; 64: 191-201.

42. Moore IF, Hughes DW, Wright GD. Tigecycline is modified by the flavin dependent monooxygenase Tetx. Biochemistry 2005; 44:

11829-35.

43. Maranan MC, Moreira B, Boyle-Vavra S, Daum RS. Antimicrobial resistance in staphylococci: Epidemiology, molecular mechanisms and clinical relevance. Infect Dis Clin North Am 1997; 11: 813-49.

44. Chang S, Sievert DM, Hageman JC, et al. Infection with vancomycin-resistant Staphylococcus aureus containing the VanA resistance gene.

N Engl J Med 2003; 348: 1342-47.

45. Hurdle JG, O'Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother 2005; 56: 1166-8.

46. Unat EK. Tıp bakteriyolojisi ve virolojisi. 2. baskı. İstanbul: Dergah Tıp yayınları; 1986. 546.

47. Töreci K. Escherichia türleri. In: Topçu AW, Söyletir G, Doğanay M (eds). Enfeksiyon hastalıkları ve mikrobiyolojisi. 2. baskı. İstanbul:

Nobel tıp kitapevleri; 2002. 1564-74.

48. Bilgehan H. Escherichia. Klinik mikrobiyoloji-Özel Bakteriyoloji ve Bakteri Enfeksiyonları. 10. baskı. İzmir: Barış yayınları; 2000. 3-17.

49. Erdem B. Enterobacteriaceae. In: Şemsettin U (ed). Temel ve klinik mikrobiyoloji. 1. baskı. İstanbul: Güneş Kitabevi; 1999. 471-515.

50. Tülek N. İnflamatuvar enteritler. İnf Hast S 2000; 3(3): 105-12.

51. Bilgehan H (ed). Klebsiella. Klinik mikrobiyoloji-Özel Bakteriyoloji ve Bakteri Enfeksiyonları. 10. baskı. İzmir: Barış yayınları; 2000. 59-68.

52. Töreci K. Klebsiella türleri. In: Topçu AW, Söyletir G, Doğanay M (eds). Enfeksiyon hastalıkları ve mikrobiyolojisi. 2. baskı. İstanbul:

Nobel tıp kitapevleri; 2002. 1575-608.

53. Kayser FH. İnfeksiyon Hastalığı Etkeni Bakteriler. In: Kayser FH, Bienz KA, Eckert J, Zinkernagel RM (eds). Tıbbi Mikrobiyoloji. 9.

baskı. İstanbul: Nobel Tıp Kitabevleri; 2002. 221-350.

54. Akalın H. Çoğul Dirençli Gram Negatif Bakteriler. In: Doğanay M, Ünal S (eds). Hastane İnfeksiyonları. Ankara: Bilimsel Tıp Yayınevi; 2003.

269-87.

55. Akova M, Ünal S, Akalın HE. Bakteriyel Pnömoniler. In: Kanra G, Akalın HE (eds). İnfeksiyon hastalıkları. 2. baskı. İstanbul: Güneş Kitabevleri; 1993. 92-109.

56. Eisenstein IB, Zaleznik FD. Enterobacteriaceae. In: Mandell GL, Benett JE, Dolin R (eds). Principles and Practice of Infectious Diseases. 5th edition. New York: Churchill Livingstone; 2000. 2294-310.

57. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010; 54(3): 969-76.

58. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18(4): 657-86.

59. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure.

Antimicrob Agents Chemother 1995; 39(6): 1211-33.

60. ß-Lactamase Classification and Amino Acid Sequences for TEM, SHV and OXA Extended-Spectrum and Inhibitor Resistant Enzymes. 2014;

www.lahey.org/studies.

61. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59(2): 165-74.

62. Harada S, Ishii Y, Yamaguchi K. Extended-spectrum beta-lactamases:

implications for the clinical laboratory and therapy. Korean J Lab Med 2008; 28(6): 401-12.

63. Chandramohan L, Revell PA. Prevalence and molecular characterization of extended-spectrum-beta-lactamase-producing Enterobacteriaceae in a pediatric patient population. Antimicrob Agents Chemother 2012; 56(9): 4765-70.

64. Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs 2010; 70(3): 313-33.

65. Endimiani A, Luzzaro F, Pini B, et al. Pseudomonas aeruginosa bloodstream infections: risk factors and treatment 111 outcome related to expression of the PER-1 extended-spectrum beta-lactamase. BMC Infect Dis 2006; 6: 52.

66. Quenaan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20: 440-58.

67. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol 2007; 2: 501-12.

68. Ikonomidis A, Tokatlidou D, Kristo I, et al. Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a bla VIM-1 metallo-beta-lactamase gene. J Clin Microbiol 2005; 43: 5344-7.

69. Gülmez D, Woodford N, Palepou MF, et al. Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss. Int J Antimicrob Agents 2008; 31: 523-6.

70. Carrër A, Poirel L, Eraksoy H, et al. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother 2008; 52: 2950-4.

71. Kollef MH. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit Care Resusc 2009; 11: 282–6.

72. Parish D, Scheinfeld N. Ceftaroline fosamil, a cephalosporin derivative for the potential treatment of MRSA infection. Curr Opin Investig Drugs 2008; 9: 201–9.

73. Corey RG, Wilcox MH, Talbot GH, et al. On behalf of the CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: 41–51.

74. Wilcox MH, Corey RG, Talbot GH, et al. On behalf of the CANVAS 2 investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 2010; 65 Suppl 4: 53–65.

75. File TM Jr, Low DE, Eckburg PB, et al. On behalf of the FOCUS 1 investigators. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: 19–32

76. Low DE, File TM Jr, Eckburg PB, et al. On behalf of the FOCUS 2 investigators. FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3: 33–44.

77. Laudano, Joseph B. "Ceftaroline fosamil: a new broad-spectrum cephalosporin." Journal of antimicrobial chemotherapy 2011; 66 suppl 3: 11-18.

78. Ishikawa T, Matsunaga N, Tawada H, et al. TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825:

synthesis, physicochemical and pharmacological properties. Bioorg Med Chem 2003; 11: 2427–37.

79. Moisan H, Pruneau M, Malouin F. Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae. J Antimicrob Chemother 2010; 65: 713–6.

80. Kosowska-Shick K, McGhee PL, Appelbaum PC. Affinity of ceftaroline and other b-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother 2010; 54: 1670–7.